** Shares of Vertex Pharmaceuticals VRTX.O fall 5.04% to $475 premarket
** Co posted Q1 revenue of $2.77 billion, missing analyst estimates of $2.85 billion according to data compiled by LSEG
** Co raised the low end of its full-year 2025 revenue forecast range to $11.85 billion from $11.75, keeping the higher end at $12 billion
** Co saw a revenue decline in Russia where Vertex's intellectual property rights is being violated
** Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized copy of co's cystic fibrosis Trikafta in Russia - William Blair
** Reports quarterly adj profit of $4.06 per share, below estimates of $4.32
** Up to last close, stock down ~24% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。